Michigan Medical Marijuana Sales Plunge to $322,350 in June 2026

Medical Program Nears Functional Extinction

Michigan's medical marijuana sales fell to $322,350 in June 2026, a 94% decline from the program's 2020 peak of $5.4 million per month. The figure represents less than 0.2% of the state's total cannabis market, which generated approximately $187 million in combined medical and adult-use sales during the same period, according to data released by the Michigan Cannabis Regulatory Agency on June 24.

Fewer than 1,800 active patients used the medical program in June. That's down from a high of 287,000 registered cardholders in 2019. The state's adult-use market, which launched in December 2019, now accounts for 99.8% of all legal cannabis transactions in Michigan.

Industry analysts point to three factors driving the collapse: price parity between medical and adult-use products, the elimination of most medical-specific tax advantages, and the convenience of adult-use retail locations, which outnumber medical-only dispensaries 412 to 9 statewide.

Adult-Use Market Absorbs Medical Demand

Adult-use sales in Michigan reached $186.7 million in June 2026, a 22% year-over-year increase that reflects the absorption of former medical patients into the recreational channel. The state collected $28.1 million in excise and sales taxes from adult-use transactions during the month, compared to $48,000 from the medical program.

The migration is economic. Medical patients in Michigan pay a 6% sales tax on purchases, while adult-use consumers pay 10% excise plus 6% sales tax. That 10-point spread once justified the $60 annual medical card fee for high-volume patients, but wholesale price compression has eroded the math.

Average retail prices for flower dropped to $4.12 per gram in June, down from $8.50 per gram in June 2023. At current prices, a patient would need to purchase more than 600 grams annually to break even on the card fee through tax savings alone. Most former medical users now buy adult-use products at lower absolute cost despite the higher tax rate.

Federal Rescheduling Uncertainty Compounds State-Level Confusion

The federal rescheduling process, stalled since the DEA's May 2024 notice of proposed rulemaking, has created operational uncertainty for Michigan operators who can't model tax exposure under a potential Schedule III regime. The DEA hasn't published a final rule or timeline for concluding the rescheduling review, leaving state-licensed businesses unable to project 280E relief or plan capital allocation for 2027.

Michigan operators currently operate under full 280E restrictions, which disallow deductions for ordinary business expenses and result in effective federal tax rates exceeding 70% for profitable retailers. If cannabis moves to Schedule III, those businesses would gain access to standard corporate deductions—but only for federally compliant activity.

Here's the problem. Michigan's medical program, while state-legal, remains federally illegal under any schedule. Adult-use programs have no federal analog. The result is a compliance gray zone where operators can't determine whether Schedule III rescheduling would apply to their state-licensed operations at all.

State Regulators Face Revenue Cliff

Michigan's Cannabis Regulatory Agency collected $48,000 in medical program taxes during June 2026, down from $810,000 in June 2023, forcing the agency to rely almost entirely on adult-use revenue to fund operations. The agency's $47 million annual budget is funded by a mix of licensing fees and a 10% earmark from adult-use excise tax collections. Medical program fees now cover less than 0.4% of regulatory costs.

State officials haven't announced plans to sunset the medical program, but the operational economics are unsustainable. The nine remaining medical-only dispensaries operate at a loss or as legacy compliance holds for vertically integrated operators who maintain medical licenses to preserve optionality under federal rescheduling scenarios.

No updates to medical program rules since 2022. No new medical dispensary licenses issued since 2021. The program exists in administrative limbo, neither officially closed nor actively managed.

Operator Strategy Shifts to Federal Compliance Optionality

Multi-state operators with Michigan footprints are maintaining dormant medical licenses as a hedge against federal rescheduling outcomes that could favor medical programs over adult-use. This strategy costs operators approximately $15,000 per year in licensing and compliance overhead per location, but preserves the ability to pivot to a federally recognized medical model if the DEA or Congress creates a pathway for state medical programs to access Schedule III benefits.

The political variable nobody can model is whether a future Congress would extend Schedule III protections to state-legal medical programs. The current rescheduling proposal applies only to FDA-approved cannabis medicines, not state dispensary systems, but legislative fixes remain possible and operators are paying to keep that door open.

Three Michigan operators interviewed for background confirmed they're maintaining medical licenses despite operating at a loss on medical sales. None would speak on the record. The calculation is pure optionality: the cost of re-entering the medical market later, if federal law changes, exceeds the cost of staying in now.

What Comes Next for Michigan's Dual-Track System

Michigan's medical marijuana program is likely to persist in name only through 2027, sustained by operators hedging federal uncertainty rather than by patient demand. The state legislature has shown no interest in formally closing the program or merging it with adult-use licensing, leaving the status quo as the path of least resistance.

Watch for the DEA's final rule on rescheduling, expected no earlier than Q4 2026. If the rule excludes state programs from Schedule III benefits, expect Michigan operators to begin surrendering medical licenses in volume. If the rule or subsequent legislation creates a compliance pathway for state medical systems, the program could see a brief resurgence as operators activate their dormant licenses to access 280E relief.

For now, Michigan's medical program is a $322,000-per-month footnote in a $2.2 billion annual adult-use market. The math is hard to argue with.